Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | frontMIND: Tafasitamab + lenalidomide + R-CHOP vs R-CHOP in high-intermediate & high-risk DLBCL

In this video, Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, discusses the rationale behind the ongoing Phase III frontMIND trial (NCT04824092), which is evaluating the safety and efficacy of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP alone in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.